Gilead Licenses Aptamer IP to Start-Up Biotech Firm Archemix | GenomeWeb

NEW YORK, Nov. 6 – Gilead Sciences has sold an exclusive license to its aptamer-based IP for $17.5 million to Archemix, a privately held biotechnology company based in Cambridge, Mass., the company announced on Tuesday.

The deal, which Archemix said will complement its existing aptamer IP, gives the company “a broad spectrum” of DNA-based tools that it plans to use in drug discovery and development, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.